JP2014506321A5

JP2014506321A5 -

Download PDF

Info

Publication number: JP2014506321A5
Authority: JP; Japan
Prior art keywords: certain embodiments; patient; corticosteroid; registered trademark; asthma
Prior art date: 2011-12-16
Legal status : Granted

Application number

JP2013544814A

Other languages

English (en)

Japanese (ja)

Other versions

JP6005657B2 (ja

JP2014506321A (ja

Filing date

2011-12-16

Publication date

2015-01-22

2011-12-16 Application filed filed Critical

2011-12-16 Priority claimed from PCT/US2011/065410 external-priority patent/WO2012083132A2/en

2014-03-13 Publication of JP2014506321A publication Critical patent/JP2014506321A/ja

2015-01-22 Publication of JP2014506321A5 publication Critical patent/JP2014506321A5/ja

2016-10-12 Application granted granted Critical

2016-10-12 Publication of JP6005657B2 publication Critical patent/JP6005657B2/ja

Status Active legal-status Critical Current

2031-12-16 Anticipated expiration legal-status Critical

Links

239000003246 corticosteroid Substances 0.000 description 16
229940125386 long-acting bronchodilator Drugs 0.000 description 14
208000006673 asthma Diseases 0.000 description 12
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 8
208000023504 respiratory system disease Diseases 0.000 description 8
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 7
239000003199 leukotriene receptor blocking agent Substances 0.000 description 7
229940124624 oral corticosteroid Drugs 0.000 description 7
PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 6
229940035073 symbicort Drugs 0.000 description 6
229960001334 corticosteroids Drugs 0.000 description 4
238000000034 method Methods 0.000 description 4
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 4
229960000278 theophylline Drugs 0.000 description 4
FCSXYHUNDAXDRH-OKMNHOJOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 FCSXYHUNDAXDRH-OKMNHOJOSA-N 0.000 description 3
RATSWNOMCHFQGJ-XODSYJLDSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-XODSYJLDSA-N 0.000 description 3
229940031472 brovana Drugs 0.000 description 3
229940085861 flovent Drugs 0.000 description 3
229940127212 long-acting beta 2 agonist Drugs 0.000 description 3
229940100119 perforomist Drugs 0.000 description 3
229960000289 fluticasone propionate Drugs 0.000 description 2
229940125369 inhaled corticosteroids Drugs 0.000 description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
229940072266 pulmicort Drugs 0.000 description 1

JP2013544814A 2010-12-16 2011-12-16 Ｔｈ２阻害に関連する診断及び治療 Active JP6005657B2 (ja)